Key points are not available for this paper at this time.
The first quarter of 2024 saw 115 agreed research and development partnerships totaling 36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs. The first quarter of 2024 saw 115 agreed research and development partnerships totaling 36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs.
Monica Hoyos Flight (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: